Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer

Abstract

Research is required in the area of non-small cell lung cancer, due to its widespread prevalence. Efforts to enhance the accessibility, evaluative simplicity, and prediction accuracy of endpoints in clinical trials are continuously being pursued. In this study, with particular emphasis on sub-groups, we examine the efficacy and impact of tyrosine kinase inhibitor (TKI) by analyzing endpoints from Phase II clinical trials. We estimated the relative treatment effects for overall survival and progression-free survival using quantitative analysis and appropriate statistical methods. We observed a highly strong and significant positive correlation between OS and PFS (r = 0.79, 95% CI = 0.75–0.83, P < 0.001), while no statistically significant difference was seen across the OS of any treatment size. Additionally, a negative correlation (very weak or no correlation, although statistically significant) between median age and overall survival (r = -0.15, 95% CI = -0.25– -0.04, P = 0.002). However, further investigation in this area of study is required.